BR9607310A - Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante - Google Patents

Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante

Info

Publication number: BR9607310A
Authority: BR; Brazil
Prior art keywords: agent; immunisuppressive; recombinant adenovirus; combining drugs; vivo
Prior art date: 1995-02-14

Application number

BR9607310A

Other languages

English (en)

Portuguese (pt)

Inventor

Jean-Francois Bach

Lucienne Chatenoud

Hedi Haddada

Michelle Webb

Michel Perricaudet

Original Assignee

Rhone Poulenc Rorer Sa

Inst Nat Sante Rech Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-14

Filing date

1996-02-12

Publication date

1997-11-25

1996-02-12 Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa

1997-11-25 Publication of BR9607310A publication Critical patent/BR9607310A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Virology (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BR9607310A 1995-02-14 1996-02-12 Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante BR9607310A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9501662A FR2730411B1 (fr)	1995-02-14	1995-02-14	Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
PCT/FR1996/000218 WO1996025177A1 (fr)	1995-02-14	1996-02-12	Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number	Publication Date
BR9607310A true BR9607310A (pt)	1997-11-25

Family

ID=9476106

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9607310A BR9607310A (pt)	1995-02-14	1996-02-12	Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante

Country Status (23)

Country	Link
US (2)	US20030004091A1 (hu)
EP (1)	EP0809516B1 (hu)
JP (1)	JPH11500430A (hu)
KR (1)	KR100402540B1 (hu)
AT (1)	ATE204481T1 (hu)
AU (1)	AU717218B2 (hu)
BR (1)	BR9607310A (hu)
CA (1)	CA2211039C (hu)
CZ (1)	CZ258197A3 (hu)
DE (1)	DE69614668T2 (hu)
DK (1)	DK0809516T3 (hu)
ES (1)	ES2163612T3 (hu)
FI (1)	FI119176B (hu)
FR (1)	FR2730411B1 (hu)
GR (1)	GR3036438T3 (hu)
HU (1)	HU222991B1 (hu)
IL (1)	IL117116A0 (hu)
MX (1)	MX9706017A (hu)
NO (1)	NO320072B1 (hu)
PT (1)	PT809516E (hu)
SK (1)	SK282235B6 (hu)
WO (1)	WO1996025177A1 (hu)
ZA (1)	ZA961161B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6451571B1 (en)	1994-05-02	2002-09-17	University Of Washington	Thymidine kinase mutants
AU4088697A (en) *	1996-08-26	1998-03-19	Chiron Corporation	Postinfection human immunodeficiency virus (hiv) vaccination therapy
EP1025242A1 (en)	1997-10-30	2000-08-09	Cornell Research Foundation, Inc.	A method of inhibiting an immune response to a recombinant vector
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
JP2003523721A (ja)	1998-12-31	2003-08-12	カイロンコーポレイション	抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
AU5470900A (en) *	1999-06-08	2000-12-28	Children's Hospital Of Philadelphia, The	Methods for preventing formation of inhibitory antibodies in the setting of genetherapy
FR2799472B1 (fr) *	1999-10-07	2004-07-16	Aventis Pharma Sa	Preparation d'adenovirus recombinants et de banques adenovirales
CA2876779A1 (en)	2000-05-12	2001-11-22	Genzyme Corporation	Modulators of tnf-.alpha. signaling
WO2003004620A2 (en)	2001-07-05	2003-01-16	Chiron, Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) *	2001-09-24	2009-08-04	University Of Saskatchewan	Porcine adenovirus E1 and E4 regions
US20030129193A1 (en) *	2001-09-27	2003-07-10	Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc.	Combined methods for tumor vasculature coaguligand treatment
WO2004047826A1 (en) *	2002-11-21	2004-06-10	Genzyme Corporation	Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
ATE493980T1 (de) *	2002-11-21	2011-01-15	Genzyme Corp	Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
AU2005213449A1 (en) *	2004-02-04	2005-08-25	The La Jolla Institute For Allergy And Immunology	Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
WO2008013918A2 (en) *	2006-07-26	2008-01-31	Myelin Repair Foundation, Inc.	Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994016065A1 (en) *	1992-12-31	1994-07-21	Exemplar Corporation	Producing cells for transplantation to reduce host rejection and resulting cells
AU5965294A (en) *	1993-01-08	1994-08-15	Exemplar Corporation	An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) *	1995-02-24	1999-02-16	The Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant adenovirus

1995
- 1995-02-14 FR FR9501662A patent/FR2730411B1/fr not_active Expired - Fee Related
1996
- 1996-02-12 KR KR1019970705594A patent/KR100402540B1/ko not_active Expired - Fee Related
- 1996-02-12 CA CA2211039A patent/CA2211039C/fr not_active Expired - Fee Related
- 1996-02-12 AT AT96903080T patent/ATE204481T1/de active
- 1996-02-12 SK SK1108-97A patent/SK282235B6/sk not_active IP Right Cessation
- 1996-02-12 US US08/894,246 patent/US20030004091A1/en not_active Abandoned
- 1996-02-12 AU AU47238/96A patent/AU717218B2/en not_active Ceased
- 1996-02-12 DE DE69614668T patent/DE69614668T2/de not_active Expired - Lifetime
- 1996-02-12 JP JP8524707A patent/JPH11500430A/ja not_active Ceased
- 1996-02-12 IL IL11711696A patent/IL117116A0/xx unknown
- 1996-02-12 EP EP96903080A patent/EP0809516B1/fr not_active Expired - Lifetime
- 1996-02-12 DK DK96903080T patent/DK0809516T3/da active
- 1996-02-12 CZ CZ972581A patent/CZ258197A3/cs unknown
- 1996-02-12 MX MX9706017A patent/MX9706017A/es unknown
- 1996-02-12 WO PCT/FR1996/000218 patent/WO1996025177A1/fr not_active Ceased
- 1996-02-12 BR BR9607310A patent/BR9607310A/pt not_active Application Discontinuation
- 1996-02-12 ES ES96903080T patent/ES2163612T3/es not_active Expired - Lifetime
- 1996-02-12 HU HU9800635A patent/HU222991B1/hu not_active IP Right Cessation
- 1996-02-12 PT PT96903080T patent/PT809516E/pt unknown
- 1996-02-13 ZA ZA961161A patent/ZA961161B/xx unknown
1997
- 1997-08-13 FI FI973323A patent/FI119176B/fi not_active IP Right Cessation
- 1997-08-13 NO NO19973724A patent/NO320072B1/no not_active IP Right Cessation
2001
- 2001-08-23 GR GR20010400947T patent/GR3036438T3/el unknown
2004
- 2004-04-14 US US10/823,682 patent/US20040265276A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO320072B1 (no)	2005-10-17
NO973724L (no)	1997-08-13
AU4723896A (en)	1996-09-04
FR2730411B1 (fr)	1997-03-28
ZA961161B (en)	1996-08-07
IL117116A0 (en)	1996-06-18
DE69614668D1 (de)	2001-09-27
WO1996025177A1 (fr)	1996-08-22
PT809516E (pt)	2002-02-28
FI119176B (fi)	2008-08-29
KR100402540B1 (ko)	2004-05-07
FI973323L (fi)	1997-08-13
DK0809516T3 (da)	2001-12-17
GR3036438T3 (en)	2001-11-30
FI973323A0 (fi)	1997-08-13
ATE204481T1 (de)	2001-09-15
US20040265276A1 (en)	2004-12-30
EP0809516B1 (fr)	2001-08-22
MX9706017A (es)	1997-11-29
CA2211039A1 (fr)	1996-08-22
SK282235B6 (sk)	2001-12-03
DE69614668T2 (de)	2002-06-27
HUP9800635A3 (en)	2000-12-28
AU717218B2 (en)	2000-03-23
KR19980702199A (ko)	1998-07-15
HUP9800635A2 (hu)	1998-07-28
FR2730411A1 (fr)	1996-08-14
NO973724D0 (no)	1997-08-13
US20030004091A1 (en)	2003-01-02
SK110897A3 (en)	1998-01-14
CZ258197A3 (en)	1997-11-12
HU222991B1 (hu)	2004-01-28
CA2211039C (fr)	2011-12-06
ES2163612T3 (es)	2002-02-01
JPH11500430A (ja)	1999-01-12
EP0809516A1 (fr)	1997-12-03

Publication	Publication Date	Title
BR9607310A (pt)	1997-11-25	Associação medicamentos de ao menos um agente imunisupressor e de ao menos um adenovirus recombinante
UA66417C2 (en)	2004-05-17	Recombinant adenovirus affecting canines, pharmaceutical composition
ES2143641T3 (es)	2000-05-16	Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
BR9609176A (pt)	1999-08-24	Composi-{es de agente biolÄgico
FI973467A0 (fi)	1997-08-22	DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
AU9676198A (en)	1999-04-23	Drug delivery and gene therapy delivery system
BR9804500B1 (pt)	2010-06-15	derivado de amida, referida composição farmacêutica e agente terapêutico.
ES2130428T3 (es)	1999-07-01	Cristales de insulina asp-b28.
AU2832297A (en)	1997-11-26	Morphogen treatment for chronic renal failure
WO2000030622A3 (de)	2000-11-02	Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen
PL317105A1 (en)	1997-03-17	Compositions containing dna and p53 damaging agents
AU4718297A (en)	1998-05-22	Improvements in or relating to diagnostic/therapeutic agents
HUP9802423A2 (hu)	1999-02-01	Hiperproliferatív megbetegedések kombinált gyógyászati kezelése
MX9805939A (es)	1998-11-30	Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
DE69700983D1 (de)	2000-01-27	Ligandgerichtete enzyme-prodrug therapie
AU2001258638A1 (en)	2001-12-03	Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
AU3651595A (en)	1996-04-09	Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases
MX9706569A (es)	1997-11-29	Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
ITRM940545A0 (it)	1994-08-25	Preparato ad uso cosmetico e/o farmaceutico, con carbone attivo e sostanze disperdenti.
MX9803093A (es)	1998-11-29	Suministro de polipeptidos biologicamente activos.
DE59609353D1 (de)	2002-07-25	Mittel zur subkutanen Verabreichung von Protein C

Legal Events

Date	Code	Title	Description
2005-08-02	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-04-17	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2008-03-18	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.